News

Supriya Lifesciences announced that the Board of Directors of the Company at its meeting held on 27 May 2026, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 50%) , subject to the approval of the shareholders.

Net profit of Supriya Lifescience rose 47.34% to Rs 74.23 crore in the quarter ended March 2026 as against Rs 50.38 crore during the previous quarter ended March 2025. Sales rose 50.20% to Rs 276.53 crore in the quarter ended March 2026 as against Rs 184.11 crore during the previous quarter ended March 2025.For the full year,net profit rose 11.26% to Rs 209.12 crore in the year ended March 2026 as against Rs 187.96 crore during the previous year ended March 2025. Sales rose 18.86% to Rs 827.88 crore in the year ended March 2026 as against Rs 696.49 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales276.53184.11 50 827.88696.49 19 OPM %35.3036.71 -35.5237.44 - PBDT100.6370.14 43 303.65268.93 13 PBT92.1364.06 44 275.24248.49 11 NP74.2350.38 47 209.12187.96 11 Powered by Capital Market - Live News

Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 27 May 2026.

Supriya Lifescience announced that the U.S. Food and Drug Administration (US FDA) conducted an inspection at the Company`s manufacturing facility located at Lote, Parshuram Industrial Area, Maharashtra, India, from 2 February 2026 to 6 February 2026. The inspection concluded with the issuance of a Form 483 containing one (1) minor observation. The Company has adequately addressed the observation and has received the Establishment Inspection Report (EIR) indicating �Voluntary Action Indicated (VAI)�, signifying a successful completion of the inspection.

Net profit of Supriya Lifescience rose 6.20% to Rs 49.68 crore in the quarter ended December 2025 as against Rs 46.78 crore during the previous quarter ended December 2024. Sales rose 11.20% to Rs 206.44 crore in the quarter ended December 2025 as against Rs 185.65 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales206.44185.65 11 OPM %34.9235.52 - PBDT74.2067.54 10 PBT67.3862.58 8 NP49.6846.78 6 Powered by Capital Market - Live News